Medcann separate listing., page-24

Morning Tank, thats correct.

An opportunity with BioHealth has presented itself since the Medcann announcement causing a shift in plans.

If we did not have the BioHalth opportunity than pursuing Medcann fit-out would pressumably haves still proceeded as best option available.

The Medcann deal secured us licenses & in return gave their management the funding to fit-out their facility via our cr with the capacity to grow bulk cannabis.

No doubt waters were been navigated by CGB to try & get Medcann into a position to produce Canntab down the track however the path to manufacturing was not mapped out, atleast for shareholders.

We needed millions to fit-out Medcann for manufacturing which we didn't have, this was a big question mark up until last week & you will recall I had a fair interest in what business plan or investor presentation they would release to market.

In short..Medcann deal was good..But taking Bonify circumstances into consideration the BioHealth deal has proceeded Medcann aquisition as the obvious path to revenue with less risk.

It saves us millions & is a clearer path to manufacturing than what we had with Medcann.

Regards, Dan.